ARCA biopharma, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the creation and commercialization of genetically targeted therapies designed to address various cardiovascular ailments. The company's leading therapeutic programs feature two key candidates: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), known as AB201, which is currently being evaluated in a Phase IIb clinical trial for its potential in treating COVID-19. Gencaro (bucindolol hydrochloride), a distinctive pharmacogenetically-targeted beta-adrenergic receptor antagonist. This compound has already concluded its Phase IIb trial, demonstrating efficacy for the management of atrial fibrillation in patients afflicted with chronic heart failure. To further its research and development efforts, ARCA biopharma has established strategic collaborations. These include a partnership with LabCorp aimed at developing a genetic test for the GENETIC-AF clinical trial, as well as a research alliance with the Colorado Prevention Center (an academic research organization of the University of Colorado) focused on advancing and commercializing Gencaro. Founded in 2004, the company is based in Westminster, Colorado.